Molecular differences in early-onset biliary tract cancer
Erman Akkus, Medical Oncology Fellow at Ankara University Faculty of Medicine, posted on X about recent paper by Thejus Jayakrishnan et al., titled “Molecular Differences With Therapeutic Implications in Early-Onset Compared With Average-Onset Biliary Tract Cancers” published on JCO Precision Oncology.
Authors: Thejus Jayakrishnan, Yasmine Baca, Joanne Xiu, Mehrie Patel, Benjamin A. Weinberg, Emil Lou, Jashodeep Datta, Moh’d Khushman, Pat Gulhati, Sanjay Goel, Tiago Biachi de Castria, Vaia Florou, Kanika G. Nair, Suneel D. Kamath, Alok A. Khorana
“Molecular differences in early-onset biliary tract cancer (EO-BTC)
5,587 patients (8.1% EO-BTC)
EO-BTC
- FGFR2 fusion (15.7% v 5.9% Q < 0.001)
- NIPBL fusion (1.1% v 0%; Q < 0.001)
- Higher angiogenesis
Average-onset-BTC
- Higher interferon gamma-IFG score
- Higher T-cell–inflamed signature
Access to NGS and FGFR targeted treatments are especially crucial for young patients.”
Source: Erman Akkus/X
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023